CORDIS - EU research results
CORDIS

Systemic Endotoxemia as the driver of chronic inflammation - Biomarkers and novel therapeutic targets for Arthritis

Project description

Rheumatic diseases: the role of the gut-joint axis

Rheumatic diseases (RD) are autoimmune and inflammatory diseases that primarily attack the joints, muscles and bones. The working hypothesis of the EU-funded ENDOTARGET project is that RDs are a result of systemic inflammation caused by gut microbiota. Researchers propose to investigate how gut microbiota may alter intestinal permeability and cause endotoxemia. They will combine omics data from patients to identify RD risk biomarkers, study the gut-joint axis and screen drugs that reduce intestinal permeability. Through an AI tool, the consortium aims to identify individuals with a risk of developing RD and support treatment decision-making.

Objective

Rheumatic diseases (RDs) affect more than 40% of Europe's population and cause significant disability, pain, reduced lifespan and a very high economic burden. In this project, we will explore the role of chronic systemic inflammation caused by intestinal microbiota derived immunologically active compounds, as a driver in the transition from health to disease, with a special focus on three RDs; osteoarthritis (OA), rheumatoid arthritis (RA), and spondylarthritis (SpA). We aim to explore the relationship between gut microbiota, intestinal permeability, and endotoxemia. We aim to understand their role as drivers of disease onset and disease activity in RA, SpA and OA, as well as targets of preventive and therapeutic approaches. We will study the events leading from health to disease onset by i) taking advantage of geographically diverse large cohorts of people with available blood and faeces samples, ii) search for novel risk biomarkers for RA, SpA, and OA by using high-throughput OMICS-based analyses iii) conducting targeted clinical studies, iv) performing in vitro mechanistic studies to explore the gut-joint axis using tissue explant cultures and organ-on-chip models v) conducting interventional proof of concept studies of diet, faecal transplantation and a gut permeability decreasing drug in RA and SpA patients, vi) exploring in vitro new potential drugs or nutraceuticals to cope with endotoxemia effects on target tissues. By combining all these results, machine learning and AI-informed rheumatic disease prediction tool will be developed for clinicians to help them identify patients with increased risk of developing the target diseases. It will thus assist in the choice of personalized blueprint intervention to reduce the risk of these diseases and disease activity in RA and SpA and to slow down the progression of OA.

Coordinator

HUS-YHTYMA
Net EU contribution
€ 1 762 493,75
Address
STENBACKINKATU 9
00029 Helsinki
Finland

See on map

Region
Manner-Suomi Helsinki-Uusimaa Helsinki-Uusimaa
Activity type
Research Organisations
Links
Total cost
€ 1 762 493,75

Participants (11)

Partners (2)